Neurocrine Biosciences Dirección

Dirección controles de criterios 3/4

El CEO de Neurocrine Biosciences' es Kevin Gorman , nombrado en Jan 2008, tiene una permanencia de 16.25 años. compensación anual total es $15.75M, compuesta por 6% salario y 94% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.51% de las acciones de la empresa, por valor de $72.09M. La antigüedad media del equipo directivo y de la junta directiva es de 6.4 años y 11.3 años, respectivamente.

Información clave

Kevin Gorman

Chief Executive Officer (CEO)

US$15.8m

Compensación total

Porcentaje del salario del CEO	6.0%
Permanencia del CEO	16.3yrs
Participación del CEO	0.5%
Permanencia media de la dirección	6.4yrs
Promedio de permanencia en la Junta Directiva	11.3yrs

Actualizaciones recientes de la dirección

Recent updates

Sosei to get $30M from Neurocrine as schizophrenia drug gets FDA nod to enter phase 2 trial

Aug 05

Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Quite Sensibly

Jul 26

Better Ingrezza Sales And A Clinical Trial Read-Out Could Reignite Neurocrine Shares

Jul 19

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Kevin Gorman en comparación con los beneficios de Neurocrine Biosciences?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$16m	US$946k	US$250m
Sep 30 2023	n/a	n/a	US$191m
Jun 30 2023	n/a	n/a	US$176m
Mar 31 2023	n/a	n/a	US$64m
Dec 31 2022	US$12m	US$860k	US$155m
Sep 30 2022	n/a	n/a	US$58m
Jun 30 2022	n/a	n/a	US$12m
Mar 31 2022	n/a	n/a	US$71m
Dec 31 2021	US$14m	US$825k	US$90m
Sep 30 2021	n/a	n/a	US$445m
Jun 30 2021	n/a	n/a	US$365m
Mar 31 2021	n/a	n/a	US$402m
Dec 31 2020	US$14m	US$775k	US$407m
Sep 30 2020	n/a	n/a	US$93m
Jun 30 2020	n/a	n/a	US$205m
Mar 31 2020	n/a	n/a	US$177m
Dec 31 2019	US$9m	US$725k	US$37m
Sep 30 2019	n/a	n/a	US$21m
Jun 30 2019	n/a	n/a	US$18m
Mar 31 2019	n/a	n/a	-US$39m
Dec 31 2018	US$9m	US$675k	US$21m
Sep 30 2018	n/a	n/a	US$10m
Jun 30 2018	n/a	n/a	-US$52m
Mar 31 2018	n/a	n/a	-US$106m
Dec 31 2017	US$8m	US$640k	-US$143m

Compensación vs. Mercado: La compensación total ($USD15.75M) de Kevin está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD13.51M).

Compensación vs. Ingresos: La compensación de Kevin ha aumentado más de un 20% en el último año.

CEO

Kevin Gorman (65 yo)

16.3yrs

Permanencia

US$15,750,812

Compensación

Dr. Kevin C. Gorman, Ph D., has been Chief Executive Officer of Neurocrine Biosciences, Inc. since January 2008 and served as its President since January 2008. Dr. Gorman is a Founder of Neurocrine Bioscie...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Kevin Gorman	CEO & Director	16.3yrs	US$15.75m	0.51% $ 70.9m
Matthew Abernethy	Chief Financial Officer	6.4yrs	US$6.06m	0.031% $ 4.3m
Jude Onyia	Chief Scientific Officer	2.4yrs	US$7.22m	0.013% $ 1.8m
Kyle Gano	Chief Business Development & Strategy Officer	13.3yrs	US$5.99m	0.13% $ 18.7m
Eiry Roberts	Chief Medical Officer	6.3yrs	US$5.87m	0.024% $ 3.3m
Jane Sorensen	Head of Investor Relations	no data	sin datos	sin datos
Darin Lippoldt	Chief Legal Officer & Corporate Secretary	9.5yrs	US$4.72m	0.040% $ 5.5m
Julie Cooke	Chief Human Resources Officer	6.6yrs	sin datos	0.018% $ 2.5m
Eric Benevich	Chief Commercial Officer	8.9yrs	US$5.81m	0.041% $ 5.6m
David Boyer	Chief Corporate Affairs Officer	4.6yrs	sin datos	0.0049% $ 674.8k
Ingrid Delaet	Chief Regulatory Officer	1.5yrs	sin datos	0.0075% $ 1.0m
Christopher O'Brien	Exclusive Consultant	6.3yrs	US$3.10m	sin datos

6.4yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de NBIX es experimentado (6.4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Kevin Gorman	CEO & Director	16.3yrs	US$15.75m	0.51% $ 70.9m
Christine Poon	Independent Director	less than a year	US$813.45k	0% $ 0
Richard Pops	Independent Director	26yrs	US$492.04k	0.029% $ 4.1m
Stephen Sherwin	Independent Director	25yrs	US$479.54k	0.022% $ 3.1m
William Rastetter	Independent Chairman of the Board	14.2yrs	US$495.04k	0.051% $ 7.1m
Gary Lyons	Independent Director	31.2yrs	US$460.11k	0.12% $ 16.1m
George Morrow	Independent Director	8.5yrs	US$479.54k	0% $ 0
Shalini Sharp	Independent Director	4.2yrs	US$497.11k	0% $ 0
Leslie Norwalk	Independent Director	4.6yrs	US$475.11k	0% $ 0
Johanna Mercier	Independent Director	3yrs	US$467.61k	0% $ 0

11.3yrs

Permanencia media

68yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de NBIX son experimentados ( 11.3 años antigüedad media).

Neurocrine Biosciences Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Chief Commercial Officer notifies of intention to sell stock

Neurocrine Biosciences, Inc., Annual General Meeting, May 22, 2024

Independent Director notifies of intention to sell stock

Independent Director notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Insider notifies of intention to sell stock

Recent updates

Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data

Neurocrine Biosciences, Inc. Launches What the C@H! Educational Initiative to Support Congenital Adrenal Hyperplasia Community

Neurocrine Biosciences, Inc. Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder

Chief Commercial Officer notifies of intention to sell stock

Neurocrine Biosciences, Inc., Annual General Meeting, May 22, 2024

Neurocrine Biosciences, Inc. Announces First-Patient Dosed in Phase 2 Clinical Study Evaluating NBI-1070770 in Adults with Major Depressive Disorder

Neurocrine Biosciences (NASDAQ:NBIX) Seems To Use Debt Rather Sparingly

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating Effects of NBI-1065890, a Second-Generation VMAT2 Inhibitor, in Healthy Adults

Independent Director notifies of intention to sell stock

Voyager Therapeutics, Inc. Announces Selection of Gene Therapy Development Candidate for Friedreich's Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

Independent Director notifies of intention to sell stock

New minor risk - Shareholder dilution

Neurocrine Biosciences Heads Into A Catalyst-Rich 2024 With Additional Upside

CEO & Director notifies of intention to sell stock

Neurocrine Biosciences, Inc. Provides Earnings Guidance for the Full Year of 2024

Insider notifies of intention to sell stock

Neurocrine Biosciences, Inc. to Report Fiscal Year 2023 Results on Feb 07, 2024

Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Price In Tune With Earnings

Insider notifies of intention to sell stock

Chief Human Resources Officer notifies of intention to sell stock

Neurocrine Biosciences (NASDAQ:NBIX) Could Easily Take On More Debt

Insider notifies of intention to sell stock

Sosei Heptares’ Partner Neurocrine Biosciences Confirms Its Plans to Evaluate Two New Muscarinic Agonist Candidates in Phase 1 Clinical Studies

Neurocrine Biosciences, Inc. Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation

Neurocrine Biosciences, Inc. Announces Settlement of INGREZZA Abbreviated New Drug Application (ANDA) Litigation

Neurocrine Biosciences, Inc. Reports Update on the Phase 2 Clinical Trial

Neurocrine Biosciences® Presents Ingrezza® (Valbenazine) Capsules Interim Data Demonstrating Sustained Improvements in Chorea Associated with Huntington's Disease Through Week 50 At Huntington Study Group 2023

Neurocrine Biosciences, Inc. Provides Sales Guidance for the Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Neurocrine Biosciences, Inc. to Report Q3, 2023 Results on Oct 31, 2023

Neurocrine Biosciences, Inc. Announces U.S. FDA Accepts New Drug Application for Ingrezza®? (Valbenazine) Oral Granules Sprinkle Formulation

Independent Director notifies of intention to sell stock

Neurocrine Biosciences, Inc. Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia (CAH)

Neurocrine Biosciences Inc. Initiates Phase 1 Clinical Study Evaluating Effects of NBI-1117570 in Healthy Adults

Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?

Independent Director notifies of intention to sell stock

Neurocrine Biosciences, Inc. Presents Data at MDS International Congress of Parkinson's Disease and Movement Disorders Demonstrating Comparable Improvement over Time in Tardive Dyskinesia Severity and Impact Following Treatment with INGREZZA (Valbenazine) Capsules

Neurocrine Biosciences, Inc. Presents New INGREZZA® (valbenazine) Capsules Data Demonstrating Early and Sustained Improvements in Chorea Associated With Huntington's Disease

CEO & Director notifies of intention to sell stock

Neurocrine Biosciences, Inc. Announces FDA Approval of INGreZZA (valbenazine) Capsules for the Treatment of Chorea Associated with Huntington's Disease

Consensus EPS estimates increase by 22%

Neurocrine Biosciences, Inc. Reiterates Sales Guidance for the Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Neurocrine Biosciences, Inc. Announces Retirement of Eiry W. Roberts as Chief Medical Officer

Neurocrine Biosciences, Inc. to Report Q2, 2023 Results on Aug 01, 2023

We Think Neurocrine Biosciences (NASDAQ:NBIX) Can Manage Its Debt With Ease

Neurocrine Biosciences, Inc. Presents INGreZZA(R) (valbenazine) Capsules Data on Tardive Dyskinesia Improvement Regardless of Baseline Antipsychotic Use at 2023 Psych Congress Elevate

Neurocrine Biosciences, Inc. Announces Publication of Full KINECT(TM)-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington's Disease in the Lancet Neurology

Neurocrine Biosciences, Inc. Presents Data on Treatment of Patients with Congenital Adrenal Hyperplasia at ECE 2023

Consensus EPS estimates fall by 23%

Neurocrine Biosciences, Inc. Reiterates Sales Guidance for the Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Chief Human Resources Officer notifies of intention to sell stock

Neurocrine Biosciences (NASDAQ:NBIX) Has A Rock Solid Balance Sheet

Insufficient new directors

CEO & Director notifies of intention to sell stock

Full year 2022 earnings: EPS misses analyst expectations

CEO & Director notifies of intention to sell stock

Neurocrine Biosciences, Inc. to Report Q4, 2022 Results on Feb 06, 2023

Independent Director exercised options and sold US$3.2m worth of stock

Neurocrine Biosciences, Inc. Announces U.S. FDA Accepts Supplemental New Drug Application for Valbenazine as A Treatment for Chorea Associated with Huntington Disease

Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-827104 in Pediatric Patients with Epileptic Encephalopathy with Continuous Spike-And-Wave During Sleep

Does Neurocrine Biosciences (NASDAQ:NBIX) Have A Healthy Balance Sheet?

Chief Commercial Officer exercised options and sold US$4.2m worth of stock

Chief Commercial Officer exercised options and sold US$2.1m worth of stock

Neurocrine Biosciences Presents Additional Phase 3 Data for KINECT-HD Study Evaluating Valbenazine for Chorea Associated with Huntington Disease at HSG 2022

Price target increased to US$127

Neurocrine Biosciences, Inc. Provides Sales Guidance for the Full-Year 2022

Insider exercised options and sold US$718k worth of stock